Baseline clinical parameters and cardiovascular risk factors which were associated with the presence of baseline or progressive plaque in PsA patients
| No plaque | Any plaque | p-value | |
|---|---|---|---|
| Age (year) | 45±11 | 54±11 | 0.001 |
| Age at PsA diagnosis (year) | 38±10 | 43±13 | 0.047 |
| PsA disease duration (year) | 7.8±6.9 | 10.6±7.3 | 0.071 |
| Age at PsO diagnosis (year) | 32±12 | 40±14 | 0.008 |
| Fasting sugar (mmol/L) | 5.3±1.1 | 5.8±1.5 | 0.089 |
| Total cholesterol (mmol/L) | 5.0±1.0 | 5.3±0.8 | 0.076 |
| Apolipoprotein B (mg/dL) | 74.9±17.9 | 89.2±15.8 | 0.002 |
PsA, psoriatic arthriti;. PsO, psoriasis.